GlaxoSmithKline has linked up with Galapagos to discover and develop new anti-infectives, the natural product compound collection and chemistry capabilities of BioFocus DPI, the Belgian firm’s services division.
Under the terms of the deal, Galapagos will receive up to 3.5 million euros in technology access fees and up to 215 million euros in development and commercial milestones. It also stands to get a double-digit royalty on sales of products from the alliance which grants GSK options to license drug candidates that are directed against up to six anti-infective discovery targets.
The Mechelen-based firm will be responsible for the discovery and development of natural product small molecule drug candidates through to 'proof of concept’ in clinical trials, at which point GSK will have the exclusive option to license each compound for further development and commercialisation on a worldwide basis.
Source: PharmaTimes
No comments:
Post a Comment